WO2010127100A8 - Compositions comprenant un antihistaminique, un antitussif et un décongestionnant dans des formulations à libération prolongée - Google Patents

Compositions comprenant un antihistaminique, un antitussif et un décongestionnant dans des formulations à libération prolongée Download PDF

Info

Publication number
WO2010127100A8
WO2010127100A8 PCT/US2010/032949 US2010032949W WO2010127100A8 WO 2010127100 A8 WO2010127100 A8 WO 2010127100A8 US 2010032949 W US2010032949 W US 2010032949W WO 2010127100 A8 WO2010127100 A8 WO 2010127100A8
Authority
WO
WIPO (PCT)
Prior art keywords
decongestant
antitussive
antihistamine
extended release
compositions
Prior art date
Application number
PCT/US2010/032949
Other languages
English (en)
Other versions
WO2010127100A1 (fr
Inventor
James Joseph Mcdermott
R. Gary Hollenbeck
Craig Linwood Attkisson
Original Assignee
Atley Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atley Pharmaceuticals, Inc. filed Critical Atley Pharmaceuticals, Inc.
Priority to CA2760688A priority Critical patent/CA2760688A1/fr
Priority to EP10770321A priority patent/EP2424363A1/fr
Priority to JP2012508723A priority patent/JP2012525423A/ja
Publication of WO2010127100A1 publication Critical patent/WO2010127100A1/fr
Publication of WO2010127100A8 publication Critical patent/WO2010127100A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur des formulations orales pour le traitement du rhume et de symptômes allergiques. Chaque formulation combine un antihistaminique, un antitussif et/ou un décongestionnant dans une composition à libération prolongée. L'invention porte en outre sur des procédés de fabrication et d'utilisation de telles formulations, ainsi que sur des procédés pour empêcher un abus ou une extraction d'un médicament unique présent dans une composition à libération prolongée orale comprenant deux ou plusieurs parmi un antihistaminique, un antitussif et/ou un décongestionnant.
PCT/US2010/032949 2009-05-01 2010-04-29 Compositions comprenant un antihistaminique, un antitussif et un décongestionnant dans des formulations à libération prolongée WO2010127100A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA2760688A CA2760688A1 (fr) 2009-05-01 2010-04-29 Compositions comprenant un antihistaminique, un antitussif et un decongestionnant dans des formulations a liberation prolongee
EP10770321A EP2424363A1 (fr) 2009-05-01 2010-04-29 Compositions comprenant un antihistaminique, un antitussif et un décongestionnant dans des formulations à libération prolongée
JP2012508723A JP2012525423A (ja) 2009-05-01 2010-04-29 抗ヒスタミン剤と鎮咳剤と充血緩和剤とを徐放性製剤中に含む組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17489109P 2009-05-01 2009-05-01
US61/174,891 2009-05-01

Publications (2)

Publication Number Publication Date
WO2010127100A1 WO2010127100A1 (fr) 2010-11-04
WO2010127100A8 true WO2010127100A8 (fr) 2010-12-29

Family

ID=43030528

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/032949 WO2010127100A1 (fr) 2009-05-01 2010-04-29 Compositions comprenant un antihistaminique, un antitussif et un décongestionnant dans des formulations à libération prolongée

Country Status (5)

Country Link
US (1) US20100278915A1 (fr)
EP (1) EP2424363A1 (fr)
JP (1) JP2012525423A (fr)
CA (1) CA2760688A1 (fr)
WO (1) WO2010127100A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012525424A (ja) * 2009-05-01 2012-10-22 アトリー ファーマシューティカルズ インコーポレイテッド 抗ヒスタミン剤と鎮咳剤と充血緩和剤とを徐放性製剤中に含む組成物
WO2013149258A2 (fr) 2012-03-30 2013-10-03 Charles Drew University of Medicine and Science Compositions et procédés de traitement ou de prévention de troubles du syndrome métabolique
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
RU2016147009A (ru) 2014-05-01 2018-06-04 Сан Фармасьютикал Индастриз Лимитед Композиции с пролонгированным высвобождением в виде суспензии
CN103977315B (zh) * 2014-05-27 2017-02-01 南方医科大学 一种治疗风热犯肺型咳嗽的药物组合物及其制备方法
CN105250240B (zh) * 2015-08-25 2017-05-17 江苏先科药业有限公司 一种含有氢可酮和氯苯那敏的口服缓释制剂
CA3008920A1 (fr) * 2015-12-23 2017-06-29 Conrig Pharma Aps Tosilate de suplatast pour le traitement de la toux associee a une maladie pulmonaire interstitielle

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4999189A (en) * 1988-11-14 1991-03-12 Schering Corporation Sustained release oral suspensions
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
CA2509429A1 (fr) * 2002-11-26 2004-06-10 University Of Maryland, Baltimore Systeme d'administration par milieu aqueux de medicaments a liberation soutenue pour medicaments electrolytiques fortement hydrosolubles
US20060018972A1 (en) * 2002-11-26 2006-01-26 Upm Pharmaceuticals, Inc. Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
US20070141147A1 (en) * 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
EP2428205B1 (fr) * 2006-03-16 2012-10-03 Tris Pharma, Inc. Formulations à libération modifiée contenant des complexes médicament - résine échangeuse d'ions
SA07280459B1 (ar) * 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8287848B2 (en) * 2006-10-03 2012-10-16 Tris Pharma Inc Formulations containing an ionic mineral-ion exchange resin complex and uses thereof
US20080085312A1 (en) * 2006-10-04 2008-04-10 Auriga Laboratories, Inc. Multi-Phase Release Potassium Guaiacolsulfonate Compositions
US20080292699A1 (en) * 2007-05-25 2008-11-27 Sovereign Pharmaceuticals, Ltd. Solid pharmaceutical dosage unit for alleviating symptoms of rhinorrhea
JP2012525424A (ja) * 2009-05-01 2012-10-22 アトリー ファーマシューティカルズ インコーポレイテッド 抗ヒスタミン剤と鎮咳剤と充血緩和剤とを徐放性製剤中に含む組成物

Also Published As

Publication number Publication date
EP2424363A1 (fr) 2012-03-07
CA2760688A1 (fr) 2010-11-04
JP2012525423A (ja) 2012-10-22
WO2010127100A1 (fr) 2010-11-04
US20100278915A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
WO2010127100A8 (fr) Compositions comprenant un antihistaminique, un antitussif et un décongestionnant dans des formulations à libération prolongée
WO2008085765A3 (fr) Formes dosifiées de petit volume de médicament contenant du sufentanil s'administrant par voie trans-muqueuse orale pour le traitement de la douleur
WO2010066749A3 (fr) Comprimés d'ulipristal acétate
WO2009121945A3 (fr) Nouvelles formulations, comprimés comprenant de telles formulations, leur utilisation et leur procédé de préparation
WO2007143155A3 (fr) Forme pharmaceutique à liberation prolongée contenant de la phényléphrine
IL193762A (en) The effective compounds in inhibiting dgat1-related disorders, their medicinal products and their use in the preparation of drugs
WO2008011194A3 (fr) Dispositifs d'administration transmuqueuse avec absorption accrue
WO2008122965A3 (fr) Compositions pharmaceutiques à base de cyclosporine
WO2008034041A3 (fr) Combinaisons thérapeutiques
WO2008146178A3 (fr) Nouvelle forme posologique de comprimé
AP2012006231A0 (en) Capsule formulation of pirfenidone and pharmaceutically acceptable excipients.
WO2003049680A3 (fr) Compositions contenant des antihistaminiques sedatifs et des antihistaminiques non sedatifs
WO2009074351A3 (fr) Formes solides de ténofovir disoproxil
WO2010132882A3 (fr) Compositions sublinguales de dexmédétomidine et leurs procédés d'utilisation
IL206296A (en) History of aminopyrazole, and their medicinal products and their use in the preparation of drugs for the prevention and treatment of diseases
WO2011014850A3 (fr) Formulations à usage topique à base d'un eutectique
WO2011104652A3 (fr) Compositions vétérinaires
WO2006138608A3 (fr) Compositions pharmaceutiques et leur utilisation
CA2668320A1 (fr) Utilisation de 3-alpha-androstanediol, eventuellement en combinaison avec un agoniste 5-ht1a, dans le traitement du dysfonctionnement sexuel
WO2009099467A3 (fr) Compositions de cyclosporine
WO2009035634A3 (fr) Cyanoaminoquinolones et tétrazoloaminoquinolones en tant qu'inhibiteurs de gsk-3
WO2006076097A3 (fr) Preparation non cristalline stable contenant du losartan
WO2009068708A3 (fr) Composition pharmaceutique à libération prolongée de somatostatine ou d'un analogue de celle-ci
WO2007131070A3 (fr) Compositions, formes pharmaceutiques et méthodes de traitement des vomissements
WO2009149058A3 (fr) Formulations de niacine à libération modifiée

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10770321

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2760688

Country of ref document: CA

Ref document number: 2012508723

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2010770321

Country of ref document: EP